ПРЕВЕНТИВНЫЙ ПОДХОД В СОВРЕМЕННОЙ НЕФРОЛОГИИ
https://doi.org/10.24884/1561-6274-2004-8-3-7-14
Аннотация
Об авторах
А. В. СмирновРоссия
И. Г. Каюков
Россия
А. М. Есаян
Россия
В. А. Добронравов
Россия
А. Г. Кучер
Россия
Ф. А. Тугушева
Россия
Список литературы
1. Locatelli F, Del Vecchio L, Pozzoni P. The importance of early detection of chronic kidney disease. Nephrol Dial Transplant 2002; 17[Suppl 11]: 27
2. Norris K, Vaughn C. The role of reninangiotensin aldosterone system in chronic kidney disease. Expert Rev Cardiovasc Ther 2003; 1(1): 5163
3. Goumenos DS, Kalliakmani P, Tsakas S et al. The remission of nephrotic syndrome with cyclosporin treatment does not attenuate the progression of idiopathic membranous nephropathy. Clin Nephrol 2004; 61(1):1724
4. Есаян АМ. Тканевая ренинангиотензиновая система почки. Новая стратегия нефропротекции. Нефрология 2002; 6(3): 816
5. Каюков ИГ, Есаян АМ, Кучер АГ, Ермаков ЮА. Роль функционально-гемодинамических механизмов в прогрессировании хронического гломерулонефрита. Нефрология 1998; 2(1): 713
6. Смирнов АВ. Дислипопротеидемии и проблемы не фропротекции. Нефрология 2002; 6(2): 814
7. Рентц Дун Б, Андерсон Ш, Бреннер Б. Гемодинамические основы прогрессирования почечных болезней. Современная нефрология. II международный нефрологический семинар. М., 1997; 162172
8. Смирнов АВ, Есаян АМ, Каюков ИГ. Хроническая болезнь почек: на пути к единству представлений. Нефрология 2002; 6(4): 1117
9. Burgess ED, Carides GW, Gerth WC et al. Losartan reduces the costs associated with nephropathy and endstage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from Canadian perspective. Can J Cardiol 2004; 20(6): 613618
10. Brenner BM, Cooper ME, De Zeew D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861 869
11. Ruilope LM, Segura J. Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence. Clin Ther 2003; 25(12): 30443064
12. Fouque D, Wang P, Laville M, Boissel JP. Low protein diets delay endstage renal disease in nondiabetic adults with chronic renal failure. Nephrol Dial Transplant 2000; 15: 19861992
13. Hayashi T, Suzuki A, Shoji T et al. Cardiovascular effect of normalizing the hematocrit level during erythropoethin in predialysis patients with chronic renal failure. Am J Kidney Dis 2000; 35: 250256
14. Jafar TH, Schmid CH, Landa M et al. Angiotensin converting enzyme inhibitors and progression of nondiabetic renal disease. A metaanalysis of patientlevel data. Ann Intern Med 2001; 135: 7387
15. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensinreceptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851860
16. Locatelli F, Del Vecchio L. How long can dialysis be postponed by low protein diet and ACE ihibitors? Nephrol Dial Transplant 1999; 13601364
17. Locatelli F, Del Vecchio L, D’Amico M, Andrulli S. Is it the agent or the pressure level that matters for renal protection in chronic nephropathies? J Am Soc Nephrol 2002; 13 [Suppl. 3]: S196S201
18. Portoles J, Torralbo A, Martin P et al. Cardiovascular effect recombinant human erythropoetin in predialysis patients. Am J Kidney Dis 1997; 29: 541548
19. Anonymous. Part 1. Executive summary. Am J Kidney Dis 2002; 39 [Suppl 1]: S17S31
20. Добронравов ВА, Царькова ОВ. Блокаторы кальциевых каналов в нефропротекции. Нефрология 2004; 8(1): 721
21. Mann JF, Gerstein HC, Pogue J et al. Cardiovascular risk in patients with early renal insufficiency: implications for the use of ACE inhibitors. Am J Cardiovasc Drugs 2003; 2(3): 157162
22. Keith DS, Nichols GA, Gullion CM et al. Longitudinal followup study outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004;164(6): 659653
23. Ravani P, Marinangeli G, Tancredi M, Malberti F. Multidisciplinary chronic kidney disease management improves survival on dialysis. J Nephrol 2003; 16(6): 870877
24. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16(1): 3141
25. Levey AS, Bosch JP, Lewis JB. et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction indication. Modification of Diet in Renal Disease Study Group . Ann Intern Med 1999; 130(6): 471
26. Frequently asked questions about GFR estimation. http://www.kidney.org
27. Смирнов АВ. Хроническая болезнь почек или хроническое заболевание почек? Нефрология 2004; 8(1): 101102
Рецензия
Для цитирования:
Смирнов А.В., Каюков И.Г., Есаян А.М., Добронравов В.А., Кучер А.Г., Тугушева Ф.А. ПРЕВЕНТИВНЫЙ ПОДХОД В СОВРЕМЕННОЙ НЕФРОЛОГИИ. Нефрология. 2004;8(3):7-14. https://doi.org/10.24884/1561-6274-2004-8-3-7-14
For citation:
Smirnov A.V., Kayukov I.G., Essaian A.M., Dobronravov V.A., Kucher A.G., Tugusheva F.A. PREVENTIVE APPROACH IN NEPHROLOGY. Nephrology (Saint-Petersburg). 2004;8(3):7-14. (In Russ.) https://doi.org/10.24884/1561-6274-2004-8-3-7-14